2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-Y0337S
    L-Cysteine-13C3,15N 202406-97-1 99.9%
    L-Cysteine-13C3,15N is the 13C- and 15N-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans.
    L-Cysteine-13C3,15N
  • HY-N0830S9
    Palmitic acid-13C 287100-87-2 98.0%
    Palmitic acid-13C is the 13C-labeled Palmitic acid (HY-N0830). Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-13C
  • HY-W010040
    4-​Hydroxyphenylpyruvic acid 156-39-8 98.63%
    4-Hydroxyphenylpyruvic acid is an intermediate in the metabolism of the amino acid phenylalanine. 4-Hydroxyphenylpyruvic acid is a substrate of 4-hydroxyphenylpyruvic acid dioxygenase (HPPA). 4-Hydroxyphenylpyruvic acid can be used in the study of HPD-related diseases, such as type III tyrosinemia and hawkinsinuria.
    4-​Hydroxyphenylpyruvic acid
  • HY-W011142
    2'-Deoxyuridine 5'-monophosphate disodium 42155-08-8 ≥98.0%
    2'-Deoxyuridine 5'-monophosphate (dUMP) disodium is a deoxynucleotide that is reductively methylated to dTMP (2'-deoxythymidine 5'-monophosphate) by bisubstrate enzyme thymidylate synthase (TS). dTMP is a nucleotide required for DNA synthesis.
    2'-Deoxyuridine 5'-monophosphate disodium
  • HY-W013100
    Cytidine-5'-triphosphate disodium 36051-68-0 ≥98.0%
    Cytidine-5'-triphosphate (Cytidine triphosphate; 5'-CTP) disodium is a nucleoside triphosphate, that is invovled in biosynthesis of DNA, RNA and lipid. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate disodium is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii.
    Cytidine-5'-triphosphate disodium
  • HY-W017006
    1-Methyl-L-histidine 332-80-9 ≥98.0%
    1-Methyl-L-histidine is an objective indicator of meat ingestion and exogenous 3-methylhistidine (3MH) intake.
    1-Methyl-L-histidine
  • HY-W040307B
    Saccharopine hydrochloride 99.84%
    Saccharopine (L-Saccharopine) hydrochloride, a lysine degradation intermediate, is a mitochondrial toxin. Lysine and α-ketoglutarate are converted into Saccharopine hydrochloride by the lysine-ketoglutarate reductase. Saccharopine hydrochloride is then oxidized to α-aminoapidate semialdehyde and glutamate by the saccharopine dehydrogenase. Saccharopine hydrochloride impairs development by disrupting mitochondrial homeostasis.
    Saccharopine hydrochloride
  • HY-15766
    GNE-617 1362154-70-8 99.58%
    GNE-617 is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC50 of 5 nM and exhibits efficacy in xenograft models of cancer.
    GNE-617
  • HY-113413
    Imidazoleacetic acid 645-65-8 99.80%
    Imidazoleacetic acid (Imidazolyl-4-acetic acid) is a blood-brain barrier-permeable full agonist of the GABAA receptor. Imidazoleacetic acid forms via histamine oxidation in the mouse brain. Imidazoleacetic acid exerts multiple neurochemical and behavioral effects. Imidazoleacetic acid induces a range of centrally mediated effects, including analgesia, sedation, hypnosis, as well as reductions in blood pressure, body temperature, isolation-induced aggression and motor activity.
    Imidazoleacetic acid
  • HY-W007087
    Valerate sodium 6106-41-8
    Valerate sodium is the sodium salt of valeric acid, a short-chain fatty acid, and exhibits oral activity. Valerate sodium reduces binge ethanol intake and decreases blood ethanol concentration in mice, while also exerting anxiolytic effects. Valerate sodium increases GABA levels, regulates epigenetics and alters gut microbiome function. Valerate sodium can be used in research related to excessive alcohol consumption.
    Valerate sodium
  • HY-10450A
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) 960404-48-2
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury.
    Dapagliflozin ((2S)-1,2-propanediol, hydrate)
  • HY-15408
    Trelagliptin 865759-25-7 99.81%
    Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).
    Trelagliptin
  • HY-112144
    TP0463518 1558021-37-6 99.25%
    TP0463518 is an orally active, competitive pan-inhibitor of hypoxia-inducible factor prolyl hydroxylases PHD1/2/3. TP0463518 competitively inhibits human PHD1 (IC50=18 nM), PHD2 (Ki=5.3 nM), and PHD3 (IC50=63 nM), and targets monkey PHD2 with an IC50 of 22 nM. TP0463518 inhibits PHD-catalyzed hydroxylation to stabilize HIFα, thereby upregulating erythropoietin (EPO) expression and enhancing intestinal iron absorption (such as increased DMT-1 and dCYTb expression), improving anemia. TP0463518 is mainly used for the research of renal anemia and inflammatory anemia.
    TP0463518
  • HY-12542A
    Dantrolene sodium hemiheptahydrate 24868-20-0 99.79%
    Dantrolene sodium hemiheptahydrate is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium hemiheptahydrate is also a calcium channel protein inhibitor. Dantrolene sodium hemiheptahydrate inhibits the release of Ca2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene sodium hemiheptahydrate offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties.
    Dantrolene sodium hemiheptahydrate
  • HY-50706A
    Selumetinib sulfate 943332-08-9 99.58%
    Selumetinib (AZD6244) sulfate is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) sulfate inhibits ERK1/2 phosphorylation. Selumetinib sulfate can penetrate the blood brain barrier (BBB).
    Selumetinib sulfate
  • HY-15991A
    Tenapanor hydrochloride 1234365-97-9 99.55%
    Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia.
    Tenapanor hydrochloride
  • HY-137978A
    Ezurpimtrostat hydrochloride 1914148-73-4 99.26%
    Ezurpimtrostat hydrochloride (GNS561 hydrochloride) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat hydrochloride inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat hydrochloride reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat hydrochloride can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders.
    Ezurpimtrostat hydrochloride
  • HY-12744
    Genz-123346 free base 491833-30-8 99.57%
    Genz-123346 free base is an orally available inhibitor of glucosylceramide synthase. Genz-123346 blocks the conversion of ceramide to glucosylceramide (GL1) and inhibits GM1 with an IC50 of 14 nM.
    Genz-123346 free base
  • HY-14229
    TGR5 Receptor Agonist 1197300-24-5 99.67%
    TGR5 Receptor Agonist (CCDC), a potent Takeda G protein-coupled receptor 5 (TGR5; GPCR19) agonist, shows improved potency in the U2-OS cells and melanophore cells with pEC50s of 6.8 and 7.5, respectively. TGR5 Receptor Agonist can induce peripheral and central hypersensitivity to bladder distension in mice, and increase intracellular Ca2+ concentration. TGR5 Receptor Agonist can also reduces food intake and improves insulin responsiveness, in diet-induced obese mice. TGR5 Receptor Agonist can be used to research diabetes, bladder hypersensitivity and anti-obesity.
    TGR5 Receptor Agonist
  • HY-21268
    Methyl linolenate 301-00-8 99.46%
    Methyl linolenate is a polyunsaturated fattly acid (PUFA). Methyl linolenate has an anti-melanogenesis activity with an IC50 of 60 μM. Methyl linolenate can also be used for studies of the mechanisms and prevention of oxidation/peroxidation of unsaturated fatty acids.
    Methyl linolenate
Cat. No. Product Name / Synonyms Application Reactivity